Therapeutic Agents and Uses Thereof
The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
1 : An agent comprising (a) an antibody or antigen-binding fragment thereof with specificity for a kallikrein protein and (b) a cytotoxic moiety.
2 . (canceled)
3 : A method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising an antibody or antigen-binding fragment thereof with specificity for a kallikrein protein.
4 . (canceled)
5 . (canceled)
6 : The agent according to claim 1 wherein the kallikrein is selected from the group consisting of prostate-specific antigen (PSA; hk3, human kallikrein gene 3) and human glandular kallikrein (hK2).
7 : The agent according to claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein has specificity for PSA.
8 - 11 . (canceled)
12 : The agent according to claim 7 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein competes for binding to PSA with an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10.
13 : The agent according to claim 12 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein comprises one or more complementarity determining regions (CDRs) of an antibody selected from the group consisting of PSA30, 4D4, 5C3, and 5A10.
14 . (canceled)
15 : The agent according to claim 1 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein has specificity for human glandular kallikrein (hK2).
16 : The agent according to claim 15 , wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein competes for binding to hK2 with an antibody selected from the group consisting of 11B6, and 7G1.
17 : The agent according to claim 16 wherein the antibody or antigen-binding fragment thereof with specificity for a kallikrein protein comprises one or more complementarity determining regions (CDRs) of an antibody selected from the group consisting of 11B6, and 7G1.
18 - 21 . (canceled)
22 : The agent according to claim 1 , wherein the cytotoxic moiety comprises one or more radioisotopes.
23 - 25 . (canceled)
26 : The agent according to claim 1 , wherein the cytotoxic moiety comprises of one or more cytotoxic drugs.
27 - 45 . (canceled)
46 : A pharmaceutical composition comprising a therapeutically effective amount of an agent according to claim 1 , and a pharmaceutically-acceptable diluent, carrier or excipient.
47 - 56 . (canceled)
57 : A method according to claim 3 wherein the agent comprises a cytotoxic moiety.
58 : A method according to claim 3 wherein the kallikrein is selected from the group consisting of prostate-specific antigen (PSA; hk3, human kallikrein gene 3) and human glandular kallikrein (hK2).
59 : A method according to claim 58 wherein the kallikrein is PSA.
60 : A method according to claim 58 wherein the kallikrein is hK2.
61 : A method according to claim 57 wherein the cytotoxic moiety comprises one or more radioisotopes.
62 : A method according to claim 57 wherein the cytotoxic moiety comprises one or more cytotoxic drugs.
63 : A method according to claim 3 wherein the prostate cancer to be treated is metastatic prostate cancer, optionally micrometastatic prostate cancer.
64 : A method according to claim 63 wherein the metastatic prostate cancer to be treated comprises metastases within the lymph system, bone (including spine, vertebrae, pelvis, ribs), rectum, bladder and/or urethra.